Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms

January 7, 2026 updated by: Huda Ahmed Abdelsabour Abdelwahab
Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

120

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

Description

Inclusion Criteria:

- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

Exclusion Criteria:

1) Patients received chemotherapy.

  1. Patients with Active bleeding
  2. Patients with recent blood transfusion (less than 2 weeks).
  3. Patients on haematinics or vitamin B 12 therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reticulocyte count
Time Frame: 1 year

Absolute peripheral blood reticulocyte count measured in patients with chronic B-cell lymphoproliferative disorders (CLPDs).

Unit of Measure: ×10⁹/L
1 year
Reticulocyte percentage
Time Frame: 1 year

Percentage of reticulocytes among total red blood cells in peripheral blood of patients with CLPDs.

Unit of Measure: %
1 year
Immature reticulocyte fraction (IRF)
Time Frame: 1 year

Proportion of immature reticulocytes in peripheral blood measured in patients with CLPDs.

Unit of Measure: %
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Huda Ahmed Abdelsabour Abdelwahab

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

December 13, 2025

First Submitted That Met QC Criteria

January 7, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 7, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AUN-FOM-CP-CLPD-RETIC-2025

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on B Chronic Lymphocytic Leukemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe